- SKYRIZI™ is an interleukin-23 (IL-23) inhibitor used for the
treatment of moderate to severe psoriasis.1
- In clinical studies, SKYRIZI™ significantly improved levels
of skin clearance after just 16 weeks and maintained clearance at
one year (52 weeks).1
- SKYRIZI™ is the only IL-23 inhibitor to arrive at a positive
conclusion with the pCPA and is currently listed on the provincial
formularies of Ontario,
Alberta, Saskatchewan, Quebec and Nova
Scotia.
- Nova Scotia lists
SKYRIZI™ on its provincial formulary effective February 06, 2020.
MONTRÉAL, Feb. 13, 2020 /CNW/ -
AbbVie (NYSE: ABBV), a global, research and development-based
biopharmaceutical company, announced today that Nova Scotia has listed SKYRIZI™ (risankizumab)
on its provincial formulary for the treatment of moderate to severe
plaque psoriasis. This announcement comes just two months
after AbbVie successfully reached an agreement with the
pan-Canadian Pharmaceutical Alliance (pCPA). Nova Scotia joins Ontario, Alberta, Saskatchewan and Quebec in bringing a much-needed treatment to
patients living with psoriasis.
SKYRIZI™ (risankizumab) is part of a collaboration between
Boehringer Ingelheim and AbbVie, with AbbVie leading development
and commercialization globally.
"Risankizumab demonstrated high levels of skin clearance and
persistence of effect. I am delighted that Dermatologists in
Nova Scotia and our patients have
a new option that can help patients achieve and maintain a high
level of treatment response", states Dr. Richard Langley MD, Professor and Director of
Research in the Division of Dermatology at Dalhousie University and a principal investigator
for the pivotal trials and senior author of the IMMhance study.
Psoriasis is a chronic condition affecting 125 million people
worldwide, including 1 million Canadians, and many patients despite
treatment still do not reach their goals or lose treatment response
over time.2-4 The most common form is plaque
psoriasis, which affects approximately 90% of patients.
5 Of these patients, 28% or approximately 325,000
Canadians are considered moderate to severe.6
"At CAPP we are always excited to hear of new treatment options
being made available to psoriasis patients. We know that,
while being a physical burden to patients, plaque psoriasis also
has a huge emotional burden on patients. When patients can
access more effective treatments and experience desired skin
clearance, this gives them not just physical comfort, but also
relief from the emotional burden of living with such a visible
condition," explains Rachael Manion,
Executive Director, Canadian Association of Psoriasis Patients.
Information regarding the provincial criteria may be found by
consulting the following link:
- Nova Scotia Department of Health - Nova Scotia Pharmacare
About SKYRIZI™
SKYRIZI™ is a novel, humanized
immunoglobulin monoclonal antibody designed to selectively inhibit
IL-23, a naturally occurring cytokine involved in inflammatory and
immune responses.1 On April
17, 2019, SKYRIZI™ received a NOC from Health Canada for the
treatment of moderate to severe plaque psoriasis in patients who
are candidates for systemic therapy or phototherapy, based on
results from clinical studies showing significant improvement in
levels of skin clearance after just 16 weeks and at 52 weeks with
every 3-month dosing in more than 2000 adult
patients.1 Four pivotal Phase 3 studies,
ultIMMa-1, ultIMMa-2, IMMvent and IMMhance evaluated more than
2,000 patients with moderate to severe plaque
psoriasis.4 Canadians living with moderate to severe
plaque psoriasis were well represented in all four of the pivotal
clinical trials leading to Health Canada's approval, showing the
Canadian leadership in this clinical development program.
SKYRIZI™ is the only IL-23 inhibitor to arrive to a positive
conclusion with the pCPA and is currently listed on the provincial
formularies of Ontario,
Alberta, Saskatchewan, Quebec, and Nova
Scotia.
About AbbVie Care
The AbbVie Care program is designed
to provide a wide range of customized services including
reimbursement and financial support, pharmacy services, lab work
reminders and coordination, personalized education and ongoing
disease management support throughout the treatment journey.
For more information, consult www.abbviecare.ca.
About AbbVie
AbbVie is a global, research and
development-based biopharmaceutical company committed to
developing innovative advanced therapies for some of the world's
most complex and critical conditions. The company's mission is to
use its expertise, dedicated people and unique approach to
innovation to markedly improve treatments across four primary
therapeutic areas: immunology, oncology, virology and neuroscience.
In more than 75 countries, AbbVie employees are working every day
to advance health solutions for people around the world. For more
information about AbbVie, please visit us
at www.abbvie.ca and www.abbvie.com. Follow
@abbvieCanada and @abbvie on Twitter or view careers on
our Facebook or LinkedIn page.
References:
- SKYRIZI™ (risankizumab) [Canadian Product Monograph].
AbbVie Corporation, April 17,
2019.
- International Federation of Psoriasis Associations. Available
at: https://ifpa-pso.com/wp-content/uploads/2017/01/Brochure-Psoriasis-is-a-serious-disease-deserving-global-attention.pdf.
Accessed March 22, 2019.
- Mroweitz, U., et al. Definition of treatment goals for moderate
to severe psoriasis: a European consensus. Arch Dermatol Res. 2011
Jan; 303(1): 1–10.
- Levin, et al. Biologic fatigue in psoriasis. J Dermatolog
Treat. 2014 Feb;25(1):78-82. doi:
10.3109/09546634.2013.826341.
- Canadian Dermatology Association – Psoriasis. Accessed on
February 5, 2020. Available at:
https://dermatology.ca/public-patients/skin/psoriasis/
- Petrella RJ, Gregory V, Luciani L, Barbeau M . Characteristics
of chronic plaque psoriasis in Canada: a retrospective database study. (PSS7)
Poster presented at ISPOR 19th Annual International Meeting,
Montréal, QC, Canada, May 2014. Accessed on February 5, 2020. Available at:
www.valueinhealthjournal.com/article/S1098-3015(14)01705-7/abstract
SOURCE AbbVie Canada